Search

Richard J Bucala

from Cos Cob, CT
Age ~67
Get Report
Also known as:
Richard Dr Bucala
Phone and address:
22 Benenson Dr, Cos Cob, CT 06807
(203) 536-9608
Related to:
Paul R Bucala, 31Nicole Bucala, 36Anne Palitz, 67
Connected to:
Misty R Bucao, 41Brooke A Bucar, 37Darline B Bucaram, 83Sandra Bucaram, 69Jose R Bucaro, 70Philip R Bucaro, 75Sarah M Bucaro, 32Michael L Bucasas, 53Antonino G Bucca, 34Barbara A Bucca, 71

Richard Bucala Phones & Addresses

  • 22 Benenson Dr, Cos Cob, CT 06807 (203) 536-9608
  • New Haven, CT
  • New York, NY
  • Newtown, CT

Work

Company: YALE UNIVERSITY SCHOOL OF MEDICINE Address: 789 Howard Ave Suite 3Rd, New Haven, CT 06519 Phones: (203) 785-4629 (203) 785-7273

Education

School / High School: Weill Cornell Medical College 1986

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 2003

Specialities

Rheumatology

Professional Records

Medicine Doctors

Richard Bucala Photo 1

Dr. Richard J Bucala, New Haven CT - MD (Doctor of Medicine)

View page
Specialties:
Rheumatology
Address:
1 Gilbert St Suite S0420, New Haven, CT 06519

800 Howard Ave, New Haven, CT 06519
(203) 785-2140 (Phone), (203) 785-6414 (Fax)

YALE UNIVERSITY SCHOOL OF MEDICINE
789 Howard Ave Suite 3Rd, New Haven, CT 06519
(203) 785-4629 (Phone), (203) 785-7273 (Fax)
Certifications:
Internal Medicine, 2003
Rheumatology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Weill Cornell Medical College
Graduated: 1986
Medical School
Brigham and Womens Hospital
Graduated: 1986
Medical School
Hosp Spec Surg
Graduated: 1986
Richard Bucala Photo 2

Richard J. Bucala

View page
Specialties:
Rheumatology, Internal Medicine
Work:
Yale University School Of Medicine Rheumatology
300 Cedar St STE 541, New Haven, CT 06519
(203) 785-2454 (phone), (203) 785-7053 (fax)
Education:
Medical School
Cornell University Weill Medical College
Graduated: 1986
Procedures:
Arthrocentesis
Conditions:
Hypertension (HTN)
Meningitis
Osteoarthritis
Languages:
English
Korean
Spanish
Description:
Dr. Bucala graduated from the Cornell University Weill Medical College in 1986. He works in New Haven, CT and specializes in Rheumatology and Internal Medicine. Dr. Bucala is affiliated with Yale New Haven Hospital.
Richard Bucala Photo 3

Richard Bucala, New Haven CT

Work:
Yale Rheumatology
800 Howard Ave, New Haven, CT 06519

Business Records

Name / Title
Company / Classification
Phones & Addresses
Richard Bucala
Medical Doctor, Scientific Dir
The Picower Institute for Medical Research
Laboratory & Clinical Medical Research
350 Community Dr, North Hills, NY 11030
Richard John Bucala
Richard Bucala MD,PHD
Internist
800 Howard Ave, New Haven, CT 06519
(203) 785-2140
Richard Bucala
Chief Executive Officer
BREITER TECH CORP
Nonclassifiable Establishments
2842 Main St #309, Glastonbury, CT 06033

Publications

Us Patents

Immunological Advanced Glycation Endproduct Crosslink

View page
US Patent:
6380165, Apr 30, 2002
Filed:
Sep 19, 1997
Appl. No.:
08/933655
Inventors:
Yousef Al-Abed - New York NY
Richard J. Bucala - Cos Cob CT
Assignee:
The Picower Institute for Medical Research - Manhasset NY
International Classification:
A61K 3800
US Classification:
514 19, 5142358, 514396, 514398, 514 8
Abstract:
There is disclosed a means for standardizing a kit that provides a means for measuring the formation of advanced glycosylation endproducts (AGEs). The present invention further provides a novel isolate AGE that is antigenic and useful for forming antibodies having utility in diagnostic assays and for standardizing diagnostic assays.

Compounds And Compositions For Treating Tissue Ischemia

View page
US Patent:
6391899, May 21, 2002
Filed:
Jul 17, 1998
Appl. No.:
09/118388
Inventors:
Kevin J. Tracey - Old Greenwich CT
Yousef Al-Abed - New York NY
Svetlana Ivanova - Astoria NY
Richard J. Bucala - Cos Cob CT
Assignee:
North Shore—Long Island Jewish Research Institute - Manhasset NY
International Classification:
A01N 4340
US Classification:
514358, 546342
Abstract:
There is disclosed a genus of compounds and pharmaceutical compositions that are protective for mitigating damage associated with tissue ischemia, particularly stroke (CNS ischemia), and ischemia of the myocardium. The present invention further provides a method for treating tissue damage caused by ischemia. Lastly, the present invention provides a method for treating tissue damage caused by providing a compound that inhibits the cytotoxic activity of 3-aminopropanal.

Compositions And Methods For Advanced Glycosylation Endproduct-Mediated Modulation Of Amyloidosis

View page
US Patent:
6410598, Jun 25, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/477364
Inventors:
Michael P. Vitek - Apex NC, 27502
Anthony Cerami - Shelter Island NY, 11964
Richard J. Bucala - New York NY, 10021
Peter C. Ulrich - Old Tappan NJ, 07675
Helen Vlassara - Shelter Island NY, 11964
Xini Zhang - Jericho NY, 11753
International Classification:
A01N 3752
US Classification:
514632, 514634, 514 20, 5142298, 514331
Abstract:
The present invention relates generally to the non-enzymatic glycosylation of amyloidogenic proteins and the consequent formation of advanced glycosylation endproducts (AGEs). It has been found that formation of AGE-amyloidogenic proteins can enhance amyloidosis. The invention further relates to compositions and methods for the prevention and treatment of amyloidosis associated with amyloid diseases, particularly neurodegenerative disease and Type II diabetes, and more particularly Alzheimers disease. In a specific example, aggregation of an amyloidogenic peptide, AP, is enhanced by the glycosylation reaction of AP to form AGE-AP as defined herein. Accordingly, the invention extends to a method for modulating the in vivo aggregation of amyloid polypeptides and associated amyloidosis by controlling the formation and presence of AGE-amyloid polypeptide. A corresponding diagnostic utility comprises the measurement of the course and extent of amyloidosis by a measurement of the presence and amount of AGEs and particularly, AGE-amyloid. An assay is included that may use the AGE-amyloid polypeptide of the present invention to identify disease states characterized by the presence of AGE-amyloid.

Inducible Phosphofructokinase And The Warburg Effect

View page
US Patent:
6413939, Jul 2, 2002
Filed:
Oct 31, 1997
Appl. No.:
08/961578
Inventors:
Richard J. Bucala - Cos Cob CT
Jason Chesney - New York NY
Robert A. Mitchell - Great Neck NY
Assignee:
The Picower Institute for Medical Research - Manhasset NY
International Classification:
A61K 4800
US Classification:
514 44, 4241301, 435 6, 5303871, 536 231, 536 245
Abstract:
There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of PFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated PFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier; and a method for finding therapeutically active anti-cancer compounds comprising screening compounds for activity to inhibit PFK-2 but not PFK.

Screening Assay For The Identification Of Inhibitors For Macrophage Migration Inhibitory Factor

View page
US Patent:
6420188, Jul 16, 2002
Filed:
Feb 16, 1996
Appl. No.:
08/602929
Inventors:
Richard Bucala - New York NY
Peter C. Ulrich - Old Tappan NJ
Xini Xhang - Jericho NY
Anthony Cerami - Shelter Island NY
Assignee:
The Picower Institute for Medical Research - Manhasset NY
International Classification:
G01N 3353
US Classification:
436500, 435 71, 549490, 549491
Abstract:
The present invention encompasses assays to identify compounds that inhibit the enzymatic activity of MIF which catalyzes the tautomerization of MIF-substrates, such as D-dopachrome to DHICA. In general, the assay is conducted in vitro by adding, mixing or combining MIF and a suitable substrate in the presence or absence of a test compound, and measuring the tautomerization of the substrate. The test compounds that inhibit tautomerization in the assay are identified as MIF inhibitors.

Compounds Having Mif Antagonist Activity

View page
US Patent:
6492428, Dec 10, 2002
Filed:
Jul 26, 2000
Appl. No.:
09/625829
Inventors:
Yousef Al-Abed - Locust Valley NY
Richard J. Bucala - Cos Cob CT
Robert A. Mitchell - Great Neck NY
Peter Senter - Seattle WA
Assignee:
The Picower Institute for Medical Research - Manhasset NY
International Classification:
A61K 3117
US Classification:
514675, 514598
Abstract:
There are disclosed methods of use and pharmaceutical compositions for two related genera of low molecular weight compounds comprising optionally substituted iminoquinone or orthoquinone ring systems. The compounds have MIF (macrophage migration inhibitory factor) antagonist activity and find utility as such. For example, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, EAE, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).

Inducible Phosphofructokinase And The Warburg Effect

View page
US Patent:
6596851, Jul 22, 2003
Filed:
Sep 25, 2000
Appl. No.:
09/670216
Inventors:
Richard J. Bucala - Cos Cob CT
Jason A. Chesney - New York NY
Robert A. Mitchell - Great Neck NY
Assignee:
The Picower Institute for Medical Research - Manhasset NY
International Classification:
C07K 1600
US Classification:
5303879, 5303877, 5303871
Abstract:
There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of iPFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated iPFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier; and a method for finding therapeutically active anti-cancer compounds comprising screening compounds for activity to inhibit iPFK-2, preferably kinase activity.

Compounds Having Mif Antagonist Activity

View page
US Patent:
6599938, Jul 29, 2003
Filed:
Oct 27, 2000
Appl. No.:
09/699258
Inventors:
Yousef Al-Abed - Locust Valley NY
Richard J. Bucala - Cos Cob CT
Assignee:
The Picower Institute of Medical Research - Manhasset NY
International Classification:
A61K 3124
US Classification:
514538, 514539, 514567, 560 9, 560 35, 560104, 562426, 562440, 562495
Abstract:
There is disclosed a genus of optionally substituted Schiff base condensation products (and the carba analogs thereof) comprising an amino acid component and a benzaldehyde component, that have MIF (macrophage migration inhibitory factor) antagonist activity. The compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases, asthma, arthritis, EAE, ARDS and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization.
Control profile
Richard J Bucala from Cos Cob, CT, age ~67 Get Report